NUVECTIS PHARMA, INC. — Net Income by Fiscal Year
5 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/83f2002e-e4d7-45cb-ab2a-1230ac0d245d/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-26.4M | 2025-01-01 – 2025-12-31 | evidence 0001104659-26-013044 |
| FY 2024 | $-19.0M | 2024-01-01 – 2024-12-31 | evidence 0001558370-25-001496 |
| FY 2023 | $-22.3M | 2023-01-01 – 2023-12-31 | evidence 0001558370-24-002497 |
| FY 2022 | $-19.1M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-003181 |
| FY 2021 | $-12.9M | 2021-01-01 – 2021-12-31 | evidence 0001558370-23-003181 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).